利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.041 秒)

    Cationic amphiphilic lipids for liposomal gene transfer
    7.
    发明授权
    Cationic amphiphilic lipids for liposomal gene transfer 失效
    阳离子两亲脂质用于脂质体基因转移

    公开(公告)号：US06268516B1

    公开(公告)日：2001-07-31

    申请号：US09230842

    申请日：1999-03-30

    申请人： Manfred Schneider ,  Oliver Keil ,  Regina Reszka ,  Detlef Groth

    发明人： Manfred Schneider ,  Oliver Keil ,  Regina Reszka ,  Detlef Groth

    IPC分类号： C07C22900

    CPC分类号： A61K48/00 ,  A61K9/1272 ,  C07C237/12 ,  C07C271/20 ,  C07C279/14 ,  C07J41/0055 ,  C07J41/0072 ,  C12N15/88

    摘要： This invention relates to the synthesis of novel cationic, amphiphilic lipids and their application as gene transfer vehicles in vitro and in vivo. For this a series of different lipids (diglycerides, steroids) were synthesized by modification with variable cationic molecules (amino acids, biogenic amines). Compounds of this kind are, due to their capability of producing complexes with polynucleotides (DNA, RNA, Antisense oligonucleotides, ribozymes etc) suitable as vectors for gene transfer (transfection).

    摘要翻译： 本发明涉及新型阳离子，两亲性脂质的合成及其在体外和体内作为基因转运载体的应用。 为此，通过用可变阳离子分子（氨基酸，生物胺）进行修饰来合成一系列不同的脂质（甘油二酯，类固醇）。 由于它们与适合作为基因转移（转染）载体的多核苷酸（DNA，RNA，反义寡核苷酸，核酶等）产生复合物的能力，这类化合物。

    Means for Inhibiting the Expression of Protein Kinase 3
    9.
    发明申请
    Means for Inhibiting the Expression of Protein Kinase 3 有权

    公开(公告)号：US20090304678A1

    公开(公告)日：2009-12-10

    申请号：US12307052

    申请日：2007-07-20

    申请人： Jorg Kaufmann ,  Oliver Keil ,  Ansgar Santel

    发明人： Jorg Kaufmann ,  Oliver Keil ,  Ansgar Santel

    IPC分类号： A61K39/395 ,  C07H21/04 ,  C12N5/06 ,  C12N15/63 ,  C12N5/10 ,  A61K31/711

    CPC分类号： C12N15/1137 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/3521

    摘要： The present invention is related to a nucleic acid molecule comprising a double-stranded structure, whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and said first stretch is at least partially complementary to a target nucleic acid, and whereby the second strand comprises a second stretch of contiguous nucleotides and said second stretch is at least partially complementary to the first stretch, whereby the first stretch comprises a nucleic acid sequence which is at least partially complementary to a nucleotide core sequence of the nucleic acid sequence according to SEQ ID NO:1 (NM_013355), or part thereof, whereby the nucleotide core sequence comprises the nucleotide sequence from nucleotide positions 482 to 500 of SEQ ID NO:1 (SEQ ID NO:2); from nucleotide positions 1555 to 1573 of SEQ ID NO:1 (SEQ ID NO:4); from nucleotide positions 1556 to 1574 of SEQ ID NO:1 (SEQ ID NO:6); from nucleotide positions 1559 to 1577 of SEQ ID NO:1 (SEQ ID NO:8); from nucleotide positions 1566 to 1584 of SEQ ID NO:1 (SEQ ID NO:10); from nucleotide positions 2094 to 2112 of SEQ ID NO:1 (SEQ ID NO:12); from nucleotide positions 2102 to 2120 of SEQ ID NO:1 (SEQ ID NO:14); from nucleotide positions 2286 to 2304 of SEQ ID NO:1 (SEQ ID NO:16); from nucleotide positions 2761 to 2779 of SEQ ID NO:1 (SEQ ID NO:18); from nucleotide positions 2763 to 2781 of SEQ ID NO:1 (SEQ ID NO:20); from nucleotide positions 2764 to 2782 of SEQ ID NO:1 (SEQ ID NO:22); from nucleotide positions 2843 to 2861 of SEQ ID NO:1 (SEQ ID NO:24); from nucleotide positions 2844 to 2862 of SEQ ID NO:1 (SEQ ID NO:26); or from nucleotide positions 2846 to 2864 of SEQ ID NO:1 (SEQ ID NO:28), preferably the nucleotide core sequence comprises the nucleotide sequence from nucleotide positions 1555 to 1573 of SEQ ID NO:1 (SEQ ID NO:4); from nucleotide positions 1556 to 1574 of SEQ ID NO:1 (SEQ ID NO:6); from nucleotide positions 1559 to 1577 of SEQ ID NO:1 (SEQ ID NO:8); from nucleotide positions 1566 to 1584 of SEQ ID NO:1 (SEQ ID NO:10); from nucleotide positions 2094 to 2112 of SEQ ID NO:1 (SEQ ID NO:12); or from nucleotide positions 2286 to 2304 of SEQ ID NO:1 (SEQ ID NO:16), whereby preferably the first stretch is additionally at least partially complementary to a region preceding the 5′ end of the nucleotide core sequence and/or to a region following the 3′ end of the nucleotide core sequence.

    Means for inhibiting the expression of protein kinase 3
    10.
    发明授权
    Means for inhibiting the expression of protein kinase 3 有权
    抑制蛋白激酶3表达的方法

    公开(公告)号：US08232256B2

    公开(公告)日：2012-07-31

    申请号：US12307052

    申请日：2007-07-20

    申请人： Jorg Kaufmann ,  Oliver Keil ,  Ansgar Santel

    发明人： Jorg Kaufmann ,  Oliver Keil ,  Ansgar Santel

    IPC分类号： C12N15/11 ,  C12N5/00 ,  C07H21/02 ,  C07H21/04 ,  C12Q1/68 ,  C12P19/34

    CPC分类号： C12N15/1137 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/3521

    摘要： The present invention is related to a nucleic acid molecule and uses thereof. The nucleic acid molecule comprises a double-stranded structure, whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and said first stretch is at least partially complementary to a target nucleic acid, and whereby the second strand comprises a second stretch of contiguous nucleotides and said second stretch is at least partially complementary to the first stretch, whereby the first stretch comprises a nucleic acid sequence which is at least partially complementary to a nucleotide core sequence of the nucleic acid sequence according to SEQ ID NO:1 (NM_013355).

    摘要翻译： 本发明涉及核酸分子及其用途。 所述核酸分子包含双链结构，由此所述双链结构包含第一链和第二链，其中所述第一链包含连续核苷酸的第一段，并且所述第一段与靶核酸至少部分互补 并且其中所述第二链包含连续核苷酸的第二段，并且所述第二段与所述第一区段至少部分互补，其中所述第一区段包含核酸序列，所述核酸序列与所述第一区段的核苷酸核心序列至少部分互补 根据SEQ ID NO：1的核酸序列（NM_013355）。